ArticleThe British journal of dermatology2022

HSP90 inhibitor RGRN-305 for oral treatment of plaque-type psoriasis: efficacy, safety and biomarker results in an open-label proof-of-concept study.

A Bregnhøj et al.PubMed ↗Publisher ↗

No numbers read from the abstract.